Ferumoxytol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates. (November 2016)

• Record Type: Journal Article
• Authors: Sankineni, Sandeep; Smedley, Jeremy; Bernardo, Marcelino; Brown, Anna M; Johnson, Linda; Muller, Berrend; Griffiths, Gary L; Kobayashi, Hisataka; Rais-Bahrami, Soroush; Pinto, Peter A; Wood, Bradford J; Keele, Brandon; Choyke, Peter L; Turkbey, Baris
• Is Part Of: Acta radiologica. Volume 57:Number 11(2016:Nov.)
• Page Start: 1396
• Page End: 1401
• Publication Date: 2016-11
• Subjects: Ferumoxytol -- lymph node -- prostate cancer -- iron oxide nanoparticles -- magnetic resonance imaging (MRI); Radiology, Medical -- Periodicals; Radiography, Medical -- Periodicals; Radiotherapy -- Periodicals; 616.0757
• DOI: 10.1177/0284185115586023
• Languages: English
• ISSNs: 0284-1851

Abstract

Background: A variety of magnetic resonance (MR) lymphographic agents have been proposed for mapping the lymph nodes draining the prostate. Purpose: To investigate the feasibility of using ferumoxytol (an FDA-approved iron oxide agent) for lymph node mapping of the prostate on imaging (MRI) in a non-human primate (NHP) Macaque model. Material and Methods: Four NHPs weighing 5–13 kg underwent injection of ferumoxytol after a needle was introduced transrectally under MRI guidance into the prostate using a commercially available intrarectal MRI biopsy guide. Ferumoxytol was administered at dosage in the range of 0.15–0.75 mg Fe/kg in a fixed injection volume of 0.2 mL. T1-weighted MRI was performed at 3 T starting immediately and extending at least 45 min post-injection. Two readers evaluated the images in consensus. The NHPs tolerated the ferumoxytol injections at all doses with no evident side effects. Results: It was determined that the lowest dose of 0.15 mg Fe/kg produced the best outcome in terms of lymph node visualization and draining nodes were reliably visualized at this dose and volume. Conclusion: Thus, MRI with intraprostatic injection of ferumoxytol may be considered an effective T1 contrast agent for prospective mapping of lymph nodes draining the prostate and, thus, for attempted sentinel lymph node identification in prostate cancer. Large clinical trials to determine safety and efficacy are needed.